Evaluating the Combined Effect of Oral Premedications on Inferior Alveolar Nerve Block Effectiveness

Model scores of the 29,894 trials active now.

Model score 9% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (741 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-11-23. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: blocksymptomaticeffective ineffectivenesshours
  Phrases that lowered it: effect ofteethis conductedpatientsbetween 18
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Number of arms: 4 (lowers risk) · Design
• Phase: 3 (lowers risk) · Design
• Drug's FAERS reports with a death: 11.7% (lowers risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Responsible party: sponsor investigator (raises risk) · Design
• Primary purpose: supportive care (lowers risk) · Design
• Blinding: quadruple (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports before start: 410552 (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 72.8% (lowers risk) · Drug's FDA history
• Sponsor's past trials: 0 (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 1 (raises risk) · Sponsor's track record
• Maximum age: 45 (lowers risk) · Who can join
• Collaborators: 1 (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Effect of Preoperative Oral Ibuprofen on Anesthetic Efficacy of Inferior Alveolar Nerve Block With Supplemental Buccal and Lingual Infiltrations Using Articaine in Mandibular Molar Teeth With Irreversible Pulpitis NCT05927922 · started 2023 · scored riskier than 6% of active trials completed
• Efficacy of Ketorolac Buccal Infiltration on Success Rate of Inferior Alveolar Nerve Block NCT02536430 · started 2015 · scored riskier than 9% of active trials completed
• Evaluation of Methylprednisolone or Ibuprofen on Efficacy of Nerve Blocks With Symptomatic Irreversible Pulpitis NCT04157036 · started 2020 · scored riskier than 12% of active trials terminated
• Efficacy of Combining an Inferior Alveolar Nerve Block With a Buccal Infiltration NCT06276842 · started 2020 · scored riskier than 6% of active trials completed
• Different Volumes of Articaine for Inferior Alveolar Nerve Block in Irreversible Pulpitis NCT05840913 · started 2023 · scored riskier than 5% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.